Go to the list of all blogs
published in Blogs
Jul 16, 2026
VIXY: Targeting $30 with +40-45% Upside in the Next Volatility Move

VIXY: Targeting $30 with +40-45% Upside in the Next Volatility Move

Key Takeaways

  • Target price: $30 per share, representing a roughly 40-45% gain from recent levels near $21, a round psychological level the ETF has crossed multiple times over the past year.
  • Strongest bullish factor: A sudden spike in equity market volatility — driven by geopolitical shock, recession fears, or a rapid equity sell-off — would directly lift VIX futures prices and propel VIXY higher.
  • Biggest obstacle: Contango, the persistent condition where longer-dated VIX futures trade above near-term contracts, imposes a structural cost every time the fund rolls positions, eroding the ETF's value during calm markets.
  • Key levels: The $20 area marks an important psychological and technical support zone near the 52-week low, while $30-$35 represents a resistance band that has capped rallies during moderate volatility events.
  • Investor takeaway: Hitting $30 is realistic during the next volatility spike, but VIXY is designed for short-term tactical use and structurally decays during extended calm — making timing the critical variable.

What VIXY Actually Tracks

The ProShares VIX Short-Term Futures ETF (VIXY) is an exchange-traded fund that tracks the S&P 500 VIX Short-Term Futures Index. Unlike a traditional equity ETF, VIXY does not hold shares of companies. Instead, it invests in a rolling portfolio of first- and second-month VIX futures contracts — financial instruments that reflect market expectations for S&P 500 volatility 30 days into the future.

This distinction matters enormously. VIXY does not track the spot Cboe Volatility Index (VIX) directly, and its performance can diverge significantly from the headline VIX number that traders watch. The fund resets exposure daily and is intended for short-term use — often measured in days or weeks, not months or years. ProShares explicitly warns that investors holding shares over longer periods "may be subject to increased risk of loss."

Where VIXY Stands Today

As of mid-July 2026, VIXY trades near $21, hovering just above its 52-week low of approximately $20.28. The ETF has declined roughly 55% over the past twelve months, consistent with a prolonged period of relatively subdued equity market volatility. The fund's assets under management (AUM) stand at approximately $198 million, with an expense ratio of 0.85% to 0.96% depending on the reporting source.

VIXY's 52-week high reached approximately $46.89, demonstrating the ETF's capacity for explosive upside moves when volatility regimes shift. The current price, sitting near the low end of this range, means a move to $30 would require recovering roughly half the distance between the 52-week low and that prior peak — a plausible scenario during elevated but not extreme market stress.

Catalysts That Could Push VIXY Toward $30

VIXY rallies when fear enters equity markets. The most direct catalyst would be a sharp S&P 500 drawdown — on the order of 5% to 10% — triggered by any of several realistic scenarios. An unexpectedly hawkish Federal Reserve pivot, disappointing earnings from mega-cap technology stocks, escalating trade tensions, or a geopolitical crisis could all send the VIX futures curve sharply higher.

Historical precedent supports the plausibility. During the most recent significant volatility events over the past year, VIXY surged from levels similar to today's into the $30-$47 range within days or weeks. The ETF's structure means that when spot VIX spikes and the futures curve shifts upward in backwardation — where near-term futures rise above longer-dated ones — VIXY can deliver rapid gains. A VIX reading moving from the mid-teens into the mid-to-high 20s would likely be sufficient to push VIXY toward the $30 level.

Market sentiment and positioning also play a role. Periods of extreme complacency, when volatility selling strategies become crowded, can set the stage for violent reversals. When the market is positioned for continued calm, even a moderate catalyst can trigger outsized moves in volatility products as traders rush to hedge.

The Main Headwind: Contango and Structural Decay

The single largest headwind is contango. In normal market conditions, longer-dated VIX futures trade at a premium to near-term contracts because uncertainty increases with time. Each day, VIXY must sell expiring front-month contracts and buy more expensive second-month contracts — a process that steadily erodes the fund's net asset value. This structural decay means VIXY can decline even when the spot VIX remains flat.

Additionally, the macroeconomic backdrop matters. If the U.S. economy continues expanding, corporate earnings hold steady, and the Fed maintains a predictable policy path, equity volatility could remain suppressed for extended periods. In that environment, VIXY would continue grinding lower rather than mounting a recovery toward $30. The fund has lost roughly 47% annualized over the past five years, illustrating how punishing a "buy and hold" approach can be.

Liquidity and fund flows represent another consideration. VIXY competes with leveraged volatility products, and its approximately $198 million in AUM is modest by ETF standards. During extreme market dislocations, the underlying VIX futures market can experience strained liquidity, potentially causing the ETF to trade at premiums or discounts to its net asset value.

Important Technical Levels to Watch

From a technical analysis perspective, the $20 zone represents a critical support area — the floor established during the most recent period of market calm. A break below this level would signal a new leg lower and likely delay any path to $30. On the upside, $25 serves as the first meaningful hurdle, followed by the psychologically important $30 round number. The $35-$38 area marks stronger resistance based on previous consolidation patterns observed during moderate volatility episodes over the past year.

Because VIXY is a derivative-based product rather than a company with earnings, traditional valuation metrics such as price-to-earnings ratios (P/E) or earnings per share (EPS) do not apply. The "valuation" is entirely a function of VIX futures pricing, market expectations for volatility, and the slope of the futures curve.

Using AI Daily Buy/Sell Signals for Better Timing

Navigating a product as fast-moving as VIXY requires disciplined timing. AI Daily Buy/Sell Signals from Tickeron provide traders with a systematic, data-driven approach to identifying opportunities across thousands of stocks and ETFs. The platform's artificial intelligence continuously monitors market conditions, technical patterns, and trend shifts to generate actionable Buy, Sell, or Hold signals. For volatility products like VIXY, where entry and exit timing can make the difference between profit and loss, having an AI-powered monitoring tool helps traders stay ahead of rapid sentiment changes without staring at screens all day. Traders can use these signals to screen for new opportunities, manage existing positions, and spot emerging trend changes more efficiently.

Putting It All Together

The question of whether VIXY can reach $30 is not a matter of "if" but rather "when" and "how quickly." The ETF has demonstrated repeatedly that it can surge to $30 and well beyond during volatility events. The structural drag of contango makes sustained moves higher unlikely without fresh market fear, and timing the entry remains the central challenge. Investors watching VIXY should monitor the VIX futures curve structure, macroeconomic catalysts, and equity market sentiment as leading indicators. A move to $30 appears realistic during the next meaningful volatility spike, but investors must recognize that this ETF is a tactical instrument, not a long-term holding, and carries the real risk of permanent capital decay if held through extended calm periods.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: VIXY

Momentum Indicator for VIXY turns negative, indicating new downward trend

VIXY saw its Momentum Indicator move below the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VIXY turned negative on August 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIXY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VIXY broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VIXY entered a downward trend on July 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VIXY advanced for three days, in of 194 cases, the price rose further within the following month. The odds of a continued upward trend are .

Industry description

The investment seeks investment results, before fees and expenses, that over time, match the performance of the S&P 500 VIX Short-Term Futures Index for a single day. The index seeks to offer exposure to market volatility through publicly traded futures markets and is designed to measure the implied volatility of the S&P 500 over 30 days in the future.
View a ticker or compare two or three
VIXY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Miscellaneous
Address
ProShares Trust II7501 WISCONSIN AVEBethesda
Phone
240-497-6400
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.